Ventripoint Diagnstcs Ltd (VPTDF)

Issued on behalf of VentriPoint Diagnostics Ltd.

Issued on behalf of VentriPoint Diagnostics Ltd.

Issued on behalf of Quantum Secure Encryption Corp.

Issued on behalf of Quantum Secure Encryption Corp.

Issued on behalf of Ventripoint Diagnostics Ltd.

Issued on behalf of VentriPoint Diagnostics Ltd.

Issued on behalf of GoldHaven Resources Corp.

Issued on behalf of Ventripoint Diagnostics Ltd.

Issued on behalf of VentriPoint Diagnostics Ltd.

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

Issued on behalf of Oncolytics Biotech Inc.

Issued on behalf of Oncolytics Biotech Inc.

Issued on behalf of Oncolytics Biotech Inc.

Toronto, Ontario - TheNewswire - (October 11, 2024) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce that it has submitted its next generation of software and hardware, VMS+4.0, for approval under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR.  

Toronto, Ontario – TheNewswire – August 22, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce that Evelina London Children’s Hospital (part of Guy's and St Thomas' NHS Foundation Trust) is the newest user to adopt the VMS+ 3.0 system upgrade.

Toronto, Ontario – TheNewswire – April 1, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be exhibiting at the 71st Annual Scientific Session and Expo, hosted by the American College of Cardiology (ACC) between April 2-4, 2022, in Washington, D.C, United States.

Toronto, Ontario – TheNewswire – August 09, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has filed an international patent application under the Patent Cooperation Treaty (PCT) to protect Ventripoint’s  recent novel improvements to its cardiac measurement technology. Ventripoint is a pioneer in application of artificial intelligence (AI) to heart analysis and this latest application strengthens the company’s intellectual property position and coverage for the Ventripoint’s flagship products.  With this one international patent application, Ventripoint registers its claim to this invention in at least 153 different contracting countries under the PCT.  

Toronto, Ontario – TheNewswire – July 5, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; (OTC:VPTDF) is pleased to announce that it  has engaged Digital257 Technologies Inc. to provide investor relations and social media services pursuant to a consulting agreement dated June 2, 2021.

Toronto, Ontario – TheNewswire – July 2, 2021 - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT) (OTC:VPTDF) announces that on July 1, 2021 the Board of Directors approved the granting of an aggregate of 850,000 options to consultants and a Director of the Corporation at an exercise price of $0.30 for a term of one year and vesting from immediately to over 9 months. The Corporation now has 1,078,685 options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting on December 14, 2020.

Ventripoint Also Provides a Financial Update

Toronto, Ontario – TheNewswire – May 6, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide this update on its financial status and the exercises of warrants and options since the last update (see NR March 3, 2021).  

Toronto, Ontario – TheNewswire – May 4, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to announce that it is receiving advisory services and research and development funding of up to $120,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to further enhance cardiac measurement capabilities of the VMS+.  This funding is a continuation of a previously successful NRC IRAP-funded project that resulted in the development of VMS+3.0.

Toronto, Ontario - The Newswire - April 27, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) announces the Company has entered into a collaboration with GE Healthcare.

Toronto, Ontario – TheNewswire – April 20, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) attended the 23rd Annual Canadian Echo Weekend – 2021 Digital Edition, which was organized by the Canadian Society of Echocardiography (CSE).

Toronto, Ontario - The Newswire - April 19, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has filed a U.S. provisional patent application for its novel cardiac measurement approach.